keyword
MENU ▼
Read by QxMD icon Read
search

Muscle invasive bladder cancer

keyword
https://www.readbyqxmd.com/read/28106542/urinary-nid2-and-twist1-methylation-to-augment-conventional-urine-cytology-for-the-detection-of-bladder-cancer
#1
Joseph J Fantony, Thomas A Longo, Ajay Gopalakrishna, Richmond Owusu, Raymond S Lance, Wen-Chi Foo, Brant A Inman, Michael R Abern
BACKGROUND: Abnormal methylation of urinary TWIST1 and NID2 conferred high sensitivity and specificity for the detection of urothelial carcinoma. OBJECTIVE: We examine the performance of the urine-based TWIST1/NID2 methylation assay with the addition of urine cytology for the detection of urothelial carcinoma. MATERIALS AND METHODS: A prospective multi-institutional study was conducted to assess the performance of a methylation assay for patients with hematuria or under surveillance for non-muscle invasive bladder cancer (NMIBC)...
January 13, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28104421/assessing-cancer-progression-and-stable-disease-after-neoadjuvant-chemotherapy-for-organ-confined-muscle-invasive-bladder-cancer
#2
Meera R Chappidi, Max Kates, Aaron Brant, Alexander S Baras, George J Netto, Phillip M Pierorazio, Noah M Hahn, Trinity J Bivalacqua
OBJECTIVE: To propose and validate a new approach to stratify clinically staged organ-confined muscle-invasive bladder cancer patients (cT2N0M0) that are pathologic non-responders to neoadjuvant chemotherapy (NAC) to better characterize NAC non-response. METHODS: We retrospectively identified radical cystectomy patients with cT2N0M0 disease at our institution (2005-2014) and in the National Cancer Database (NCDB, 2004-2012) for external validation. Patients were stratified as stable (pT2N0M0) or progressors (>pT2 and/or pN+)...
January 16, 2017: Urology
https://www.readbyqxmd.com/read/28101348/evans-blue-mediated-white-light-detection-of-non-muscle-invasive-bladder-cancer-a-preclinical-feasibility-and-safety-study-using-a-rat-bladder-urothelial-cell-carcinoma-model
#3
Sanne Elsen, Evelyne Lerut, Frank Van Der Aa, Ben Van Cleynenbreugel, Hendrik Van Poppel, Peter De Witte
Photodynamic diagnosis (PDD) improves the detection of non-muscle-invasive bladder cancer (NMIBC). However, white-light (WL) cystoscopy remains the technique routinely used in urological clinics. A more cost-effective but equally performant alternative to PDD may encompass the use of an intense tumoritropic dye in combination with WL cystoscopy. Using a preclinical setting, we investigated the practical aspects of the use of Evans blue (EB) dye for the possible future detection of NMIBC using WL cystoscopy...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28075465/monoclonal-antibody-zt-g4-targeting-ron-receptor-tyrosine-kinase-enhances-chemosensitivity-of-bladder-cancer-cells-to-epirubicin-by-promoting-g1-s-arrest-and-apoptosis
#4
Jun-Feng Chen, Bi-Xia Yu, Rui Yu, Liang Ma, Xiu-Yi Lv, Yue Cheng, Qi Ma
Epirubicin (EPI) is one of the most used intravesical chemotherapy agents after transurethral resection to non-muscle invasive bladder tumors (NMIBC) to prevent cancer recurrence and progression. However, even after resection of bladder tumors and intravesical chemotherapy, half of them will recur and progress. RON is a membrane tyrosine kinase receptor usually overexpressed in bladder cancer cells and associated with poor pathological features. This study aims to investigate the effects of anti-RON monoclonal antibody Zt/g4 on the chemosensitivity of bladder cells to EPI...
February 2017: Oncology Reports
https://www.readbyqxmd.com/read/28074276/in-stage-pt1-non-muscle-invasive-bladder-cancer-nmibc-high-krt20-and-low-krt5-mrna-expression-identify-the-luminal-subtype-and-predict-recurrence-and-survival
#5
Johannes Breyer, Ralph M Wirtz, Wolfgang Otto, Philipp Erben, Maximilian C Kriegmair, Robert Stoehr, Markus Eckstein, Sebastian Eidt, Stefan Denzinger, Maximilian Burger, Arndt Hartmann
Differential expression of cytokeratins (CK) is a characteristic feature of chemoresistant luminal (KRT20) and chemosensitive intrinsic aggressive basal (KRT5) subtypes in muscle-invasive bladder cancer (MIBC). We investigated mRNA expression of KRT5 and KRT20 and its predictive value in stage pT1 bladder cancer. In retrospective analysis of clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder, a single-step RT-qPCR was used to measure mRNA expression...
January 10, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28069289/liquid-biopsy-analysis-of-fgfr3-and-pik3ca-hotspot-mutations-for-disease-surveillance-in-bladder-cancer
#6
Emil Christensen, Karin Birkenkamp-Demtröder, Iver Nordentoft, Søren Høyer, Kirstin van der Keur, Kim van Kessel, Ellen Zwarthoff, Mads Agerbæk, Torben Falck Ørntoft, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
BACKGROUND: Disease surveillance in patients with bladder cancer is important for early diagnosis of progression and metastasis and for optimised treatment. OBJECTIVE: To develop urine and plasma assays for disease surveillance for patients with FGFR3 and PIK3CA tumour mutations. DESIGN, SETTING, AND PARTICIPANTS: Droplet digital polymerase chain reaction (ddPCR) assays were developed and tumour DNA from two patient cohorts was screened for FGFR3 and PIK3CA hotspot mutations...
January 6, 2017: European Urology
https://www.readbyqxmd.com/read/28065960/urinary-bladder-cancer-in-adults-a-histopathological-experience-from-madinah-saudi-arabia
#7
Abeer Abdalla El-Siddig, Abdulkader Mohammed Albasri, Akbar Shah Hussainy, Ahmed Safar Alhujaily
OBJECTIVE: To delineate the frequency and clinicopathological features of urinary bladder cancer. METHODS: This retrospective study was conducted at the King Fahd Hospital, Madinah, Saudi Arabia, and comprised medical records related to bladder tumours, from January 2006 to October 2015. Data was obtained from histopathologic reports and evaluated for age, gender, cystoscopic findings and histopathological characteristics at the time of presentation. RESULTS: Of the 116 cases, 96(82...
January 2017: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/28065394/characterizing-intermediate-risk-non-muscle-invasive-bladder-cancer-implications-for-the-definition-of-intermediate-risk-and-treatment-strategy
#8
Kazuhiro Matsumoto, Eiji Kikuchi, Yoshinori Yanai, Nozomi Hayakawa, Yujiro Ito, Takahiro Maeda, Hirohiko Nagata, Akira Miyajima, Mototsugu Oya
PURPOSE: Patients with intermediate-risk non-muscle-invasive bladder cancer have traditionally been defined as those not included in the low- or high-risk groups. Therefore, the intermediate-risk group consists of heterogeneous patients. MATERIALS AND METHODS: We reviewed 326 patients diagnosed with intermediate-risk tumors. We subclassified these patients into 3 groups according to their clinical courses. Group A included patients with initial and multiple low-grade tumors (N = 170)...
January 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28064545/androgen-receptor-activation-a-prospective-therapeutic-target-for-bladder-cancer
#9
Taichi Mizushima, Kathleen A Tirador, Hiroshi Miyamoto
Patients with non-muscle-invasive or muscle-invasive bladder cancer undergoing surgery and currently available conventional therapy remain having a high risk of tumor recurrence or progression, respectively. Novel targeted molecular therapy is therefore expected to improve patient outcomes. Meanwhile, substantially higher incidence of bladder cancer in men has prompted research on androgen-mediated androgen receptor (AR) signaling in this malignancy. Indeed, preclinical evidence has suggested that AR signaling plays an important role in urothelial carcinogenesis and tumor outgrowth as well as resistance to some of the currently available conventional non-surgical therapies...
January 19, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28060766/opposing-roles-of-pik3ca-gene-alterations-to-ezh2-signaling-in-non-muscle-invasive-bladder-cancer
#10
Cristina Segovia, Mónica Martínez-Fernández, Marta Dueñas, Carolina Rubio, Fernando F López-Calderón, Clotilde Costa, Cristina Saiz-Ladera, María Fernández-Grajera, José Duarte, Huberto García Muñoz, Federico de la Rosa, Felipe Villacampa, Daniel Castellano, Jesús M Paramio
The high rates of tumor recurrence and progression represent a major clinical problem in non-muscle invasive bladder cancer. Previous data showed that EZH2-dependent signaling mediates these processes, whereas the frequent alterations of PIK3CA gene (copy gains and mutations) are predictive of reduced recurrence. Here we show, using clinical samples and bladder cancer cell lines, a functional interaction between EZH2- and PIK3CA-dependent signaling pathways. PIK3CA alterations mediated, on the one hand, the increased expression of two miRNAs, miR-101 and miR-138, which posttranscriptionally downregulate EZH2 expression...
January 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28058776/guideline-of-guidelines-non-muscle-invasive-bladder-cancer
#11
REVIEW
Solomon L Woldu, Aditya Bagrodia, Yair Lotan
Non-muscle invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, however this definition represents a spectrum of disease with a variable clinical course notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with a goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, however adherence to management principles amongt practicing urologists is reportedly low...
January 6, 2017: BJU International
https://www.readbyqxmd.com/read/28050795/how-different-cystoscopy-methods-influence-patient-sexual-satisfaction-anxiety-and-depression-levels-a-randomized-prospective-trial
#12
Wojciech Krajewski, Katarzyna Kościelska-Kasprzak, Joanna Rymaszewska, Romuald Zdrojowy
PURPOSE: Bladder cancer (BC) is one of the most common cancers worldwide. BC diagnosis and surveillance is based on cystoscopy (CS). CS impact on patient's depression, anxiety, and sexual satisfaction (SS) is not sufficiently studied. There are no data on patient's comfort with flexible or rigid CS. METHODS: We prospectively evaluated pain perception (PP), depression, anxiety, and SS of 100 male patients who previously underwent at least one rigid CS in our department as surveillance after TURB procedure due to non-muscle-invasive BC and were scheduled for the next CS examination...
January 3, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28049550/gec-estro-acrop-recommendations-for-performing-bladder-sparing-treatment-with-brachytherapy-for-muscle-invasive-bladder-carcinoma
#13
Bradley R Pieters, Elzbieta van der Steen-Banasik, Geert A Smits, Marisol De Brabandere, Alberto Bossi, Erik Van Limbergen
The standard treatment for muscle-invasive bladder cancer (MIBC) is a radical cystectomy with pelvic lymph node dissection with or without neoadjuvant chemotherapy. In selected cases a bladder sparing approach is possible, for example a limited surgical excision combined with external beam radiotherapy and brachytherapy. To perform brachytherapy flexible catheters have to be implanted in the bladder wall. The implantation is done either by the open retropubic approach or the endoscopic surgical approach. The largest experience for brachytherapy is with low-dose rate and pulsed-dose rate, although some short-term experience with high-dose rate is also reported...
December 31, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28049011/fgfr3-tert-and-otx1-as-urinary-biomarker-combination-for-surveillance-of-bladder-cancer-patients-in-a-large-prospective-multicenter-study
#14
Willemien Beukers, Kirstin A van der Keur, Raju Kandimalla, Yvonne Vergouwe, Ewout W Steyerberg, Joost L Boormans, Jorgen B Jensen, José A Lorente, Francisco X Real, Ulrike Segersten, Torben F Orntoft, Nuria Malats, Per-Uno Malmström, Lars Dyrskjot, Ellen C Zwarthoff
PURPOSE: Non-muscle invasive bladder cancer (NMIBC) patients are followed with frequent cystoscopies. In this study FGFR3, TERT and OTX1 are investigated as a diagnostic urinary marker combination during follow-up of patients with primary NMIBC. MATERIAL AND METHODS: In this international multi-center prospective study 977 NMIBC patients were included. Urines (n= 2496) were collected prior to cystoscopy during regular visits. Sensitivity was estimated for detection of concomitant recurrences...
December 31, 2016: Journal of Urology
https://www.readbyqxmd.com/read/28048054/su-f-j-05-the-effect-of-air-pockets-in-the-urinary-bladder-during-bladder-hyperthermia-treatment
#15
G Schooneveldt, H P Kok, A Bakker, E D Geijsen, T M de Reijke, J Crezee
PURPOSE: Hyperthermia combined with Mitomycin C is used for the treatment of non-muscle invasive bladder cancer (NMIBC), using a phased array system of microwave antennas for bladder heating. Often some air is present in the bladder, which effectively blocks the microwave radiation, potentially preventing proper treatment of that part of the bladder. Air can be a relevant fraction of the bladder content and large air pockets are expected to have a noticeable influence on achieved temperatures...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28043166/pharmacokinetic-drug-evaluation-of-atezolizumab-for-the-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma
#16
Rutveej Patel, Megan Bock, Charles F Polotti, Sammy Elsamra
Muscle invasive bladder cancer (MIBC) is difficult to manage for patients who progress during or after initial chemotherapy regimens. Current regimens offer low response rates with high toxicities. The advent of immune checkpoint inhibitors may represent a new opportunity for effective management of these patients. Areas covered: Atezolizumab is an engineered humanized monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. It is administered intravenously and is given every 3 weeks as long as there is no evidence of tumor progression...
February 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28041998/bacillus-calmette-guerin-strain-may-not-effect-recurrence-free-survival-when-used-intravesically-with-interferon-alpha2b-for-non-muscle-invasive-bladder-cancer
#17
Ryan L Steinberg, Nathan A Brooks, Lewis J Thomas, Sarah L Mott, Michael A O'Donnell
OBJECTIVES: Adjuvant intravesical Bacillus Calmette-Guerin (BCG) remains the standard-of-care for high-grade non-muscle-invasive bladder cancer (NMIBC). Conflicting reports exist regarding disparate outcomes among BCG strains. We sought to determine whether a difference in recurrence-free survival (RFS) existed between TICE BCG and Connaught BCG strains used with interferon (IFN) for the treatment of NMBIC. MATERIALS AND METHODS: A post hoc analysis of the phase 2 BCG/IFN study, conducted from May 1999 to February 2001...
December 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/28040351/clinical-outcomes-of-patients-with-histologic-variants-of-urothelial-cancer-treated-with-trimodality-bladder-sparing-therapy
#18
Ross E Krasnow, Michael Drumm, Hannah J Roberts, Andrzej Niemierko, Chin-Lee Wu, Shulin Wu, Jing Zhang, Niall M Heney, Matthew F Wszolek, Michael L Blute, Adam S Feldman, Richard J Lee, Anthony L Zietman, William U Shipley, Jason A Efstathiou
BACKGROUND: Trimodality bladder-sparing therapy (TMT) is an acceptable treatment for selected patients with muscle-invasive urothelial cancer. Outcomes of TMT in histologic variants remains largely unknown. OBJECTIVE: To compare outcomes of pure urothelial carcinoma (PUC) to variant urothelial carcinoma (VUC) after TMT. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of patients treated with TMT at a single cancer center from 1993 until 2013...
December 28, 2016: European Urology
https://www.readbyqxmd.com/read/28039452/preoperative-neutrophil-lymphocyte-ratio-can-significantly-predict-mortality-outcomes-in-patients-with-non-muscle-invasive-bladder-cancer-undergoing-transurethral-resection-of-bladder-tumor
#19
Minyong Kang, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
The prognostic role of systemic inflammatory response (SIR) markers is unclear in patients with non-muscle invasive bladder cancer (NMIBC). Here, we aimed to investigate the prognostic role of various SIR markers in the oncological outcomes in non-muscle invasive bladder cancer (NMIBC) patients at a single institution in Korea. Neutrophil-lymphocyte ratio (NLR), derived-NLR (dNLR), and platelet-lymphocyte ratio (PLR) were examined as SIR markers. We retrospectively collected data of 1,698 NMIBC patients who underwent transurethral resection of the bladder (TURB) between 1990 and 2013...
December 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/28035618/who-1973-grade-3-and-infiltrative-growth-pattern-proved-aberrant-e-cadherin-expression-tends-to-be-of-predictive-value-for-progression-in-a-series-of-stage-t1-high-grade-bladder-cancer-after-organ-sparing-approach
#20
Wolfgang Otto, Johannes Breyer, Sonja Herdegen, Fabian Eder, Simone Bertz, Matthias May, Roman Mayr, Eva M Lausenmeyer, Stefan Denzinger, Bas W G van Rhijn, Maximilian Burger, Arndt Hartmann
PURPOSE: Stage pT1 urothelial bladder cancer (UBC) is characterized as a challenging subentity of urothelial carcinoma with an unforeseeable clinical course. In addition to more or less established clinical and histopathological features, we evaluated the role of epithelial-mesenchymal transition (EMT) marker E-cadherin, shown to be of prognostic value in muscle-invasive disease, regarding the prognosis of stage pT1 high-grade (hg) UBC. METHODS: Tissue of 226 stage pT1 hg UBC patients from transurethral resection could be immunostained for E-cadherin...
December 29, 2016: International Urology and Nephrology
keyword
keyword
21307
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"